Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Should SDC 1801 fail in phase 1 human trials then it would spell curtains for SDC 1802 as similar but not identical compounds.
I have no concerns whatsoever with regards to 'our Tyk2 Jak1 compounds successfully passing phase 1 toxicity trials in humans.
We can only wait at the moment for news to land with regards to the CTA and acceptance thereof and an update on capsule manufacture. MM's will let the price slide south on news. It is not just Sareum they do this with, it is all AIM shares.
SRA 737 likewise, we will hear nothing until GSK have decided on a business plan with what compounds they now have in their pipeline.
Sweet FA can be done in the meantime apart from wait. Speculation is good. If it were not none of us would be here. As a poster put here the only factual information we get is via RNS and that at times is open to interpretation.
Regards
Hi NDR - I understand what you're saying but it might be a little bit melodramatic to say, 'The future of Sar really does hang in the balance...'. We know the tox was good and as you point out, 80% pass P1 therefore I'd say a failure would be unlikely.
If 1801 fails then we still have 737, 1802, SKIL and that FLT+Aurora doohicky to tip the balance back in our favour.
Siennaj it’s the only reason that points to why PH haven’t so far been able to attract II. They were appointed last year and the BOD rationale behind the appointment was to consolidate and make Sar more attractive to II. Toxicology has come and gone, phase 1 should start in a few months. You either position yourself before or after. £3 is still reasonable given the level some of the HNWI came in. Perhaps there will be an announcement in the next couple of months regarding II but it just depends on the appetite for risk. The future of Sar really does hang in the balance as regards to the outcome of the forthcoming trial for anyone who says pharma is a safe sector. I agree PH may have put out this note to encourage II. It will become clearer before the year is out. But so far PH clients have declined the risk and the odds of success are difficult to work out exactly but 80% of drugs do pass phase 1.
Evening NDR, wouldn't that be a bold strategy to wait until after P1 is complete?
As the trial end approaches, the sp will surely rise on expectation. The second the results are known, the sp will surge (or plummet!) accordingly. PH may have some clout but they're joint brokers - wouldn't our BoD announce trial results to their joint brokers simultaneously?
And in any case, I dare say early data may be passed to prospective partners. Hmmm, a successful trial followed immediately by license announcement? It could happen.
Nd r . Why do u say peel hunt are holding the share price back. I'm no seasoned investor but wouldn't they postpone putting a buy note up to the £3 mark if they wanted to keep price down because surely putting out that note would normally put the share price up?
It looks like PH are holding s/p back until after phase 1 completed successfully and then get II in quick with less risk and great upside.
Londonwolfie, your words on 10th April 2022:
"HDB. I would likely get access to any note that PH produce. I know I can’t share it on here but I will set up a new email address which I will post on here and use that to take requests from anyone on here and forward the note"
Able to share that email address?
Thank you, Potnak and HBD.
My prior working assumption had been late Q1 for the results. Obviously it would be great if they come within this year.
B.
Hi BB,
If we assume the CTA is submitted at the end of this month, average time for approval of P1 CTA is given on page 10 of the following doc:
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1068910/04_April_2022.pdf
Thereafter it shouldn't take too long to rustle up healthy volunteers. More info here - https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/phase-1-clinical-trials/
I would certainly hope that we could see results in late November/mid-Dec but that's just my guess.
Billy - CHK1 trial started May 2016, we got a licencing deal in Sept 2016 but I don't think we ever got a P1 trial ended RNS. Sierra was presenting data from the trial as early as Oct, I think. If the trial starts before Sept\Oct we might get a data readout this year. We might also get a licence this year.
There was nothing tangible they could say in the last RNS. They don't know anything! But when filing the CTA, they could state that it is a P1a and although safety is the primary endpoint the secondary endpoint is to monitor certain bio immune responses. The healthy patients in P1 will still have an immune response and the P1a can capture that data. That is tangble news that the market will want to hear.
Hi Potnak, based on Tim’s track record I’m not convinced that “…they will use anything tangible to create a buzz”. Sareum just don’t do ‘buzz’! That said I would guess that Stephen Parker is keen to get the SP shifting a bit.
Sorry Potnak ... I normally agree with most of what you say on this board but i have to challenge your latest statement .. "they will use anything tangible to create a buzz. "
They had a prime opportunity to elaborate in their last RNS ... but they went the usual monotone route ... as is TM's way ... they have not demonstrated a single time via their statements that they would do 'anything tangible' to create a buzz around SAREUM
Does anyone have a feel for how long its likely to take for the P1 data to be published? Lets assume the CTA is submitted at the end of this month, then two months for the CTA to be approved. Takes Sareum to the end of September. Assume then say a month lead in to starting the trials. End of October. So, how long then from that point to run the trial, collate the trial data and finally publish it?
My opinion is the board want to see the SP higher than it is now. Possibly as high as £5 so all investors are in profit. The HNWI were probably given assurances at the time of investing. So with this in mind, they will use anything tangible to create a buzz. The CTA, although a known is something the can realease to the market and because it is a P1a they are going for, then we will get some data on potential efficacy in a short period. If positive and shows safe and the right immune response. That will blow the doors off.
Hi Potnak - completely agree with the £3 minimum. Once the CTA is submitted I think we may see a surge upwards.
(I think SOG suggested they might not RNS the 1801 CTA news but as they've previously RNS'd for trials I'd hope to see something this month.)
My trade at 9:51 is showing as a sell.
Whether the note is aimed at PI's or II's, we will see some movement. 3 quid should be the minimum we sit at anyway.
Hi LondonW - thanks for the update. Funnily enough, yesterday I was just thinking about what you'd posted a while back - that a broker note wouldn't be for us punters but you might be in a position to get your hands on it. Top work!
Regards.
I should add that Bloomberg has confirmed the initiation and PT, so he's not making it up potnak!!
I only have that snippet myself sent by one of my friends who knows that I have an interest in Sareum. I haven't seen the full note yet but may get it sent to me later on
I just snook in a cheeky 2k trade just in case this is true.
Have you got a link for this?
can you share the link please
Well - they have initiated coverage today with a 304p target price.
"After the Biotech rout of 1H22, investors should start looking for where Pharma will see mispriced assets: ideally those with minimal near-term cash requirement for clinical development, yet with strong therapeutic applications. Sareum has what we think is an overlooked asset class in the UK investment landscape: small molecules. Sareum’s lean business model looks to licence its promising assets to Pharma after early-stage clinical development (mitigating pipeline risk), and its ‘kinase inhibitor’ assets have potential applications across cancer and autoimmune disease. We see fair value of 304p (c.60% upside). Buy"